Cardiovascular Drugs Practice Questions

Q: Which of the following enzymes is not targeted by hypolipidemic drugs?

Peripheral decarboxylase. ***Peripheral decarboxylase*** - **Peripheral decarboxylase** (also known as DOPA decarboxylase) is involved in the synthesis of dopamine from L-DOPA and is a target for drugs used in **Parkinson's disease**, not hypolipidemic drugs. - Its inhibition by drugs like **carbidopa** or **benserazide** prevents the peripheral conversion of L-DOPA to dopamine, increasing L-DOPA availability for the brain. *HMG Co A reductase* - **HMG-CoA reductase** is the rate-limiting enzyme in cholesterol biosynthesis and is the primary target for **statins** (e.g., atorvastatin, simvastatin). - Statins effectively lower **LDL cholesterol** by inhibiting this enzyme, reducing endogenous cholesterol production. *Lipoprotein lipase* - **Lipoprotein lipase (LPL)** activity can be enhanced by certain hypolipidemic drugs, such as **fibrates**, which activate **PPAR-α**. - Increased LPL activity leads to enhanced hydrolysis of **triglycerides** from VLDL and chylomicrons, reducing triglyceride levels in plasma. *Acyl CoA, cholesterol acyl transferase 1* - **Acyl-CoA:cholesterol acyltransferase (ACAT) inhibitors** were developed as potential hypolipidemic agents to prevent cholesterol esterification and absorption. - While not widely used clinically due to efficacy and side effect profiles, **ACAT1** is involved in cholesterol esterification in the intestine and liver, making it a target for reducing cholesterol absorption.

Q: In a diabetic patient with hypertension, which of the following medications is the most suitable choice for management?

Enalapril. ***Enalapril*** - **ACE inhibitors** like enalapril are first-line agents in diabetic patients with hypertension due to their **renoprotective effects**, slowing the progression of **diabetic nephropathy**. - They reduce **glomerular pressure** and **albuminuria**, which is crucial in managing long-term complications of diabetes. *Propranolol* - **Beta-blockers** like propranolol can mask symptoms of **hypoglycemia** (e.g., tremors, palpitations), which is a significant concern in diabetic patients. - They may also worsen **insulin resistance** and negatively impact the lipid profile. *Clonidine* - **Clonidine**, an alpha-2 agonist, is typically reserved for **resistant hypertension** or specific conditions like **ADHD** due to its side effects. - It can cause significant **sedation**, **dry mouth**, and **rebound hypertension** upon sudden discontinuation, making it less suitable for routine management. *Hydrochlorothiazide* - **Thiazide diuretics** can cause adverse metabolic effects in diabetic patients, including **hyperglycemia** and worsening of **insulin resistance**. - While effective for hypertension, their metabolic profile makes them less preferred as a first-line agent in patients with diabetes.

Q: All are fibric acid derivatives except which of the following?

Lovastatin. ***Lovastatin***- **Lovastatin** is an example of a **statin drug**, which works by inhibiting **HMG-CoA reductase**, the rate-limiting enzyme in cholesterol synthesis, primarily lowering LDL cholesterol [1, 2].- Unlike fibric acid derivatives, statins do not primarily target **PPAR-alpha** receptors to reduce triglyceride levels.*Clofibrate*- **Clofibrate** is an older **fibric acid derivative** that primarily activates **PPAR-alpha** receptors, leading to decreased triglyceride production and increased lipoprotein lipase activity [1, 2].- It is one of the earliest drugs in this class, though now largely replaced by newer agents due to side effects.*Gemfibrozil*- **Gemfibrozil** is a commonly used **fibric acid derivative** that activates **PPAR-alpha**, resulting in a reduction of **triglycerides** and an increase in **HDL cholesterol** [1, 2].- It is effective in treating severe hypertriglyceridemia and mixed dyslipidemia.*Fenofibrate*- **Fenofibrate** is a **fibric acid derivative** that, like gemfibrozil, acts as a **PPAR-alpha agonist** to lower triglycerides and raise HDL cholesterol [1, 2].- It also has a beneficial effect on **uric acid levels** and can be used in patients with hyperuricemia.

Q: How much decrease in LDL cholesterol and how much increase in HDL cholesterol can occur with the use of bile acid resins as anti-dyslipidemic drugs?

15-25% decrease in LDL-C and 3-5% increase in HDL-C. ***Correct: 15-25% decrease in LDL-C and 3-5% increase in HDL-C***- **Bile acid resins** (cholestyramine, colestipol, colesevelam) effectively lower **LDL cholesterol by 15-25%** by sequestering bile acids in the intestine, leading to increased hepatic LDL receptor expression [1].- They produce a modest but beneficial **3-5% increase in HDL cholesterol**.- This represents the typical therapeutic effect at standard doses.*Incorrect: 3-5% decrease in LDL-C and 1-3% increase in HDL-C*- This represents a **much smaller effect** on both LDL-C and HDL-C than typically observed with therapeutic doses of bile acid resins.- Such marginal LDL-C reduction (3-5%) would be **clinically insignificant** for most dyslipidemic patients requiring treatment.*Incorrect: 25-35% decrease in LDL-C and 1-3% increase in HDL-C*- While bile acid resins can achieve significant **LDL-C reduction**, the 25-35% range is on the **higher end** of what's typically seen (more common with maximum doses or combination therapy).- The **HDL-C increase of 1-3%** is lower than the standard 3-5% increase commonly reported for this drug class.*Incorrect: 5-10% decrease in LDL-C and 1-3% increase in HDL-C*- This magnitude of **LDL-C reduction is suboptimal** for patients requiring lipid-lowering therapy with bile acid resins.- Both the LDL-C decrease and HDL-C increase are below the expected therapeutic range for this medication class.

Q: Which of the following drugs is primarily indicated for improving symptoms in congestive heart failure?

Diuretics. ***Diuretics*** - **Diuretics** are the PRIMARY agents for **symptom relief** in congestive heart failure. - They directly target fluid overload, providing immediate relief of symptoms like **dyspnea** and **edema**. - According to ACC/AHA guidelines, diuretics are recommended for **all CHF patients with fluid retention** for symptom management. - While they improve quality of life significantly, their main role is **symptom control** rather than mortality reduction. *ACE inhibitor* - **ACE inhibitors** are foundational in heart failure treatment, primarily improving **mortality** and preventing **cardiac remodeling**. - They reduce preload and afterload by inhibiting the **renin-angiotensin-aldosterone system**. - While they do improve symptoms secondarily through hemodynamic effects, their **primary indication** is mortality benefit and disease modification, not direct symptomatic relief. *Beta blockers* - While essential for **reducing mortality** and improving left ventricular function in heart failure, beta-blockers' primary aim is not direct symptomatic relief. - They can initially worsen symptoms in some patients due to a **negative inotropic effect**, although this usually improves over time. - Their main benefit is long-term mortality reduction and prevention of disease progression. *Aldosterone antagonist* - **Aldosterone antagonists** (e.g., spironolactone, eplerenone) are added to therapy to reduce **mortality** and hospitalizations in patients with reduced ejection fraction. - While they can help with fluid balance, their primary benefit is blocking the harmful effects of **aldosterone** on the heart and kidneys, not direct symptom improvement.

Q: What is the drug of choice in paroxysmal supraventricular tachycardia?

Adenosine. ***Adenosine*** - **Adenosine** is the drug of choice for acute termination of most paroxysmal supraventricular tachycardias (PSVT) due to its rapid onset and short duration of action [1]. - It works by transiently blocking the **atrioventricular (AV) node**, interrupting the re-entrant circuit common in PSVT [1]. *Amiodarone* - **Amiodarone** is a potent antiarrhythmic primarily used for both supraventricular and ventricular arrhythmias, but it is not the first-line agent for acute PSVT due to a slower onset of action and more significant side effects. - It is typically reserved for **refractory arrhythmias** or for maintaining sinus rhythm in patients with recurrent atrial fibrillation or flutter. *Lidocaine* - **Lidocaine** is primarily used for **ventricular arrhythmias**, particularly in the setting of acute myocardial infarction. - It has little to no efficacy in treating **supraventricular tachycardias** because its main action is on ventricular sodium channels. *Quinidine* - **Quinidine** is a Class IA antiarrhythmic drug used for various supraventricular and ventricular arrhythmias, but it is not the first-line treatment for acute PSVT. - Its use has declined due to a high incidence of side effects like **QT prolongation**, torsades de pointes, and gastrointestinal upset.

Q: Which anti-hypertensive drug is known to cause a positive Coombs' test, indicating potential autoimmune hemolytic anemia?

Methyldopa. ***Methyldopa*** - **Methyldopa** is a well-known antihypertensive drug that can induce a **positive Coombs' test** in a significant number of patients, indicating the presence of antibodies on red blood cells. - While many patients with a positive Coombs' test remain asymptomatic, a small percentage can develop **autoimmune hemolytic anemia**. *Clonidine* - **Clonidine** is an alpha-2 adrenergic agonist used to treat hypertension but is not typically associated with inducing a **positive Coombs' test** or hemolytic anemia. - Its primary side effects relate to its central nervous system action, such as **sedation** and **dry mouth**. *Hydralazine* - **Hydralazine** is a direct vasodilator that can cause a **drug-induced lupus-like syndrome**, but it is generally not associated with a **positive Coombs' test** or hemolytic anemia. - The lupus-like syndrome presents with symptoms like arthralgia, myalgia, and fever. *Sodium nitroprusside* - **Sodium nitroprusside** is a potent vasodilator used in hypertensive emergencies, working by releasing nitric oxide. - It is not associated with a **positive Coombs' test** or drug-induced hemolytic anemia; its primary toxicity concern is **cyanide poisoning** with prolonged or high-dose use.

Q: Which of the following is the MOST effective agent for prophylaxis of high-altitude pulmonary edema?

Acetazolamide. ***Acetazolamide*** - **Acetazolamide** is a **carbonic anhydrase inhibitor** and the **first-line prophylactic agent** for high-altitude pulmonary edema (HAPE). - It works by inducing **metabolic acidosis**, which stimulates **ventilation** and improves **oxygenation**, facilitating acclimatization to high altitude. - It reduces the incidence of **acute mountain sickness (AMS)** and has proven efficacy in **HAPE prevention** by improving arterial oxygenation and reducing pulmonary artery pressure. - Recommended dosing: **125-250 mg twice daily**, starting 1-2 days before ascent. *Nifedipine* - **Nifedipine** is a calcium channel blocker that causes pulmonary vasodilation and reduces pulmonary arterial pressure. - While effective for HAPE prevention, it is typically reserved as a **second-line agent** or for individuals with a **history of recurrent HAPE**. - It is more commonly used for **treatment** of established HAPE rather than primary prophylaxis. *ACE inhibitor* - **ACE inhibitors** primarily affect the systemic renin-angiotensin-aldosterone system and are used for **hypertension** and **heart failure**. - They do not have a direct role in reducing **pulmonary artery pressure** or preventing HAPE. - Not recommended for altitude illness prophylaxis. *Digoxin* - **Digoxin** is a cardiac glycoside used for **heart failure** and **atrial fibrillation** to increase cardiac contractility and control heart rate. - It has no role in preventing or treating **HAPE** as it does not reduce pulmonary vascular resistance or facilitate acclimatization. - Not used for altitude-related conditions.

Q: SLE-like reactions are caused by?

Hydralazine. ***Hydralazine*** - **Hydralazine**, an antihypertensive, is a well-known cause of **drug-induced lupus erythematosus (DILE)**, characterized by symptoms mimicking systemic lupus erythematosus (SLE) [1]. - DILE often presents with **arthralgia, myalgia, fever, serositis**, and the presence of **anti-histone antibodies** [1]. - **Hydralazine** is the **second most common cause of DILE** (after procainamide), with higher risk in slow acetylators. - Other drugs causing DILE include procainamide, isoniazid, quinidine, minocycline, and phenytoin [1]. *Rifampicin* - **Rifampicin** is an antibiotic primarily used for tuberculosis and is known for causing **hepatotoxicity**, **red-orange discoloration of body fluids**, and **gastrointestinal disturbances**. - It does not typically induce an SLE-like reaction. *Furosemide* - **Furosemide** is a **loop diuretic** used to treat edema and hypertension, primarily causing **electrolyte imbalances** (e.g., hypokalemia, hyponatremia) and **ototoxicity** at high doses [2]. - It is not associated with drug-induced lupus erythematosus. *Paracetamol* - **Paracetamol (acetaminophen)** is an analgesic and antipyretic, and its main adverse effect is **hepatotoxicity** when taken in overdose [3]. - It is not known to cause SLE-like reactions.

Q: Which beta-blocker is known to cause decreased libido and impotence?

Atenolol. ***Atenolol*** - **All beta-blockers can cause sexual dysfunction** including decreased libido and impotence, primarily through **peripheral mechanisms** (reduced cardiac output, decreased peripheral blood flow) and effects on the autonomic nervous system. - **Atenolol** is a **hydrophilic (water-soluble)** beta-1 selective blocker with **poor CNS penetration**, so its effects on sexual function are mainly through peripheral mechanisms rather than central effects. - While sexual dysfunction is a recognized class effect of beta-blockers (occurring in 10-15% of patients), there is **no strong evidence that Atenolol causes this side effect significantly more than other beta-blockers**. - The question may be testing awareness that sexual dysfunction is a known side effect of beta-blocker therapy in general. *Propranolol* - **Propranolol** is a **lipophilic (fat-soluble)** non-selective beta-blocker that **readily crosses the blood-brain barrier**. - Due to its CNS penetration, it can cause sexual dysfunction through both **central and peripheral mechanisms**. - Sexual dysfunction with Propranolol is well-documented and occurs at similar rates to other beta-blockers. *Metoprolol* - **Metoprolol** is a **moderately lipophilic** beta-1 selective blocker with moderate CNS penetration. - Sexual dysfunction is a recognized side effect, occurring at rates similar to other beta-blockers in the class. - Effects are dose-dependent and may vary between immediate and extended-release formulations. *Carvedilol* - **Carvedilol** is a non-selective beta-blocker with additional **alpha-1 blocking activity** that causes vasodilation. - Sexual dysfunction can occur, though the alpha-1 blockade may theoretically provide some peripheral vascular benefit. - Like all beta-blockers, it carries the class warning for sexual dysfunction.

Question 1

Which of the following enzymes is not targeted by hypolipidemic drugs?

Accepted Answer

Peripheral decarboxylase

Answer

HMG Co A reductase

Answer

Lipoprotein lipase

Answer

Acyl CoA, cholesterol acyl transferase 1

Question 2

In a diabetic patient with hypertension, which of the following medications is the most suitable choice for management?

Accepted Answer

Enalapril

Answer

Clonidine

Answer

Hydrochlorothiazide

Answer

Propranolol

Question 3

All are fibric acid derivatives except which of the following?

Accepted Answer

Lovastatin

Answer

Clofibrate

Answer

Gemfibrozil

Answer

Fenofibrate

Question 4

How much decrease in LDL cholesterol and how much increase in HDL cholesterol can occur with the use of bile acid resins as anti-dyslipidemic drugs?

Accepted Answer

15-25% decrease in LDL-C and 3-5% increase in HDL-C

Answer

3-5% decrease in LDL-C and 1-3% increase in HDL-C

Answer

25-35% decrease in LDL-C and 1-3% increase in HDL-C

Answer

5-10% decrease in LDL-C and 1-3% increase in HDL-C

Question 5

Which of the following drugs is primarily indicated for improving symptoms in congestive heart failure?

Accepted Answer

Diuretics

Answer

Beta blockers

Answer

ACE inhibitor

Answer

Aldosterone antagonist

Question 6

What is the drug of choice in paroxysmal supraventricular tachycardia?

Accepted Answer

Adenosine

Answer

Amiodarone

Answer

Quinidine

Answer

Lidocaine

Question 7

Which anti-hypertensive drug is known to cause a positive Coombs' test, indicating potential autoimmune hemolytic anemia?

Accepted Answer

Methyldopa

Answer

Clonidine

Answer

Hydralazine

Answer

Sodium nitroprusside

Question 8

Which of the following is the MOST effective agent for prophylaxis of high-altitude pulmonary edema?

Accepted Answer

Acetazolamide

Answer

ACE inhibitor

Answer

Nifedipine

Answer

Digoxin

Question 9

SLE-like reactions are caused by?

Accepted Answer

Hydralazine

Answer

Rifampicin

Answer

Furosemide

Answer

Paracetamol

Question 10

Which beta-blocker is known to cause decreased libido and impotence?

Accepted Answer

Atenolol

Answer

Propranolol

Answer

Metoprolol

Answer

Carvedilol

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?